UBS Group Analysts Give Carl Zeiss Meditec (ETR:AFX) a €162.00 Price Target

Carl Zeiss Meditec (ETR:AFX – Get Rating) has been assigned a €162.00 ($172.34) target price by UBS Group in a report issued on Thursday, Borsen Zeitung reports. UBS Group’s price objective would indicate a potential upside of 18.99% from the stock’s current price.

A number of other research firms have also issued reports on AFX. Hauck Aufhäuser Investment Banking set a €195.00 ($207.45) target price on shares of Carl Zeiss Meditec in a report on Monday, February 6th. Deutsche Bank Aktiengesellschaft set a €175.00 ($186.17) target price on Carl Zeiss Meditec in a research note on Friday, February 24th. Finally, Berenberg Bank set a €138.00 ($146.81) target price on shares of Carl Zeiss Meditec in a research note on Monday, February 13th.

Carl Zeiss Meditec Trading Down 0.3 %

Shares of ETR:AFX opened at €136.15 ($144.84) on Thursday. The firm has a market capitalization of $12.18 billion, a price-to-earnings ratio of 49.85, a price-to-earnings-growth ratio of 3.75 and a beta of 0.80. The business’s 50 day moving average price is €131.14 and its 200-day moving average price is €124.59. The company has a debt-to-equity ratio of 6.30, a current ratio of 3.32 and a quick ratio of 2.47. Carl Zeiss Meditec has a 1 year low of €101.75 ($108.24) and a 1 year high of €154.05 ($163.88).

Carl Zeiss Meditec Company Profile

(Get Rating)

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers offers products and solutions for the diagnosis and treatment of chronic eye diseases; and systems and consumables for refractive surgery.